Compare CRDL & DOGZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRDL | DOGZ |
|---|---|---|
| Founded | 2017 | 2003 |
| Country | Canada | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Miscellaneous manufacturing industries |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.6M | 153.5M |
| IPO Year | 2017 | 2017 |
| Metric | CRDL | DOGZ |
|---|---|---|
| Price | $1.31 | $0.94 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 935.4K | 25.3K |
| Earning Date | 05-14-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.88 | $0.81 |
| 52 Week High | $1.71 | $16.59 |
| Indicator | CRDL | DOGZ |
|---|---|---|
| Relative Strength Index (RSI) | 63.70 | 49.48 |
| Support Level | $0.95 | $0.86 |
| Resistance Level | $1.36 | $1.06 |
| Average True Range (ATR) | 0.10 | 0.10 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 95.96 | 72.51 |
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
Dogness (International) Corp designs, manufactures pet products, including leashes and smart products, and lanyards. The company designs, processes, and manufactures fashionable and high-quality leashes, collars, and harnesses to complement cats' and dogs' appearances, as well as intelligent pet products. The company also provides dyeing services to external customers, as well as pet grooming services. The dyeing service is to utilize the existing production capacity and the pet grooming service is immaterial. Geographically, it generates maximum revenue from Mainland China and also has a presence in the United States, Europe, Australia, Canada, Central, and South America, Japan, and other Asian countries and regions.